The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 29, 2014
Filed:
Aug. 17, 2009
Ronald P. Gladue, Stonington, CT (US);
Bradley T. Keller, Chesterfield, MO (US);
Shinji Ogawa, Chesterfield, MO (US);
Arvind Rajpal, San Francisco, CA (US);
Laurie A. Tylaska, Preston, CT (US);
Shelley Sims Belouski, Camarillo, CA (US);
Larry L. Green, San Francisco, CA (US);
Meina Liang, Fremont, CA (US);
Ronald P. Gladue, Stonington, CT (US);
Bradley T. Keller, Chesterfield, MO (US);
Shinji Ogawa, Chesterfield, MO (US);
Arvind Rajpal, San Francisco, CA (US);
Laurie A. Tylaska, Preston, CT (US);
Shelley Sims Belouski, Camarillo, CA (US);
Larry L. Green, San Francisco, CA (US);
Meina Liang, Fremont, CA (US);
Pfizer Inc., New York, NY (US);
Amgen Fremont Inc., Thousand Oaks, CA (US);
Abstract
Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.